Mert joined Durin Technologies as Chief Executive Officer in 2023 and has over 20 years of experience in various sectors including Life Sciences, Diagnostics, Medical Devices, and Pharmaceutical industries. Throughout his career, he led US, EU, and global teams in matrix organizations, driving simplification, efficiency, and customer satisfaction while gaining deep expertise in product marketing, key account management, and customer relationship management.

Mert has a strong scientific background with a PhD in Cell Biology / Neuroscience, is a mentor and an entrepreneur for various individuals / companies and co-founded a CDMO company providing process development and optimization services for the bioprocess industry.

Dr. Nagele, Founder and Chief Scientific Officer of Durin Technologies, is a Professor of Geriatrics and Gerontology at the New Jersey Institute for Successful Aging at Rowan University. He obtained his PhD from Rutgers University and post-doctoral training at Rutgers Medical School.  For much of the past 20 years, he has focused on the cellular and molecular mechanisms associated with the initiation and progression of neurodegenerative diseases, especially the role of blood-brain barrier compromise and brain-reactive autoantibodies in Alzheimer’s Disease. Dr. Nagele has published more than 130 research articles in peer reviewed journals, has served as the research thesis mentor for more than 50 PhD, DO/PhD, and MS students, and has mentored numerous medical, graduate, and undergraduate students. Dr. Nagele is the recipient of numerous awards, including a State of New Jersey Senate and General Assembly Joint Legislature Resolution in recognition of his development of a new diagnostic test for Alzheimer’s Disease, the Ginsburg “Alzheimer’s Visionary Award”, the Beehler Research Mentor of the Year Award, the 2016 and 2017 Global Innovator Award from Rowan University, the 2017 Health Institute of New Jersey Research Award, and the 2020 Research Council of New Jersey Edison Patent Award.

Dennis, having joined Durin in August 2024 as the Chief Strategy and Commercial Officer, brings over 20 years of expertise in the diagnostics, lab tools, and pharmaceutical sectors. Previously, he served as the President and Founder of the Hutchison Group, where he advised several early-stage companies in the in vitro diagnostics (IVD) and next-generation sequencing (NGS) sectors, focusing on early-stage strategy and commercialization. Before that, Dennis was the Chief Commercial Officer at Svar Life Science in Malmö, Sweden, where he led commercial efforts for immunology-based products, diagnostics, lab services, commercial operations, and business development.

Earlier in his career, Dennis held multiple roles at Thermo Fisher Scientific, including developing, building, and leading the companion diagnostics team for Phadia in Uppsala, Sweden. He also played a key role in establishing the Corporate Accounts team. During his tenure at Thermo Fisher, Dennis received numerous awards for his financial performance and innovative contributions.

Dennis holds a B.A. in Molecular Biology from Boston University and a J.D. in Intellectual Property Law and Corporate Finance from Suffolk University Law School.

 Dr. Suer received her PhD in medical genetics at Gulhane Military Medical Academy in Turkey, and completed her postdoctoral residency/fellowship training program in clinical molecular genetics at the National Institute of Health Genomic Research Institute (NIH-NHGRI). Additionally, she did clinical post-doc fellowship with Dr Eric Hoffman, Dr Wang on neurological disorders at Children's National Med Center. She is a diplomate of the American Board of Medical Genetics and Genomics (ABMGG), a fellow of the American College of Medical Genetics and Genomics (ACMG), is certified by the NYS DOH as a clinical director in molecular genetic testing and a member of the American College of Medical Genetics. 

Dr. Suer previously established genetics training programs as training laboratory site director through Harvard University at Quest Diagnostics, and served as a program director, and Associate Professor at Mount Sinai Icahn School of Medicine for the ABMGG Laboratory Genetics Training Program. Recently developed autism, and other neurological disorder LDT genomic panels at Quadrant Biosciences successfully get test NYSDOH approval and test launch. She has extensive experience in molecular test biomarker development, genomics and neurological disorders and diagnostic space.

Dr. DeMarshall is the Head of Research at Durin Technologies., with more than a decade of experience in bioinformatics and neurodegenerative disease diagnostics. She received a BA in Cell Biology and Neuroscience from Rutgers University, an MS in Biomedical Science from the University of Medicine and Dentistry of New Jersey and her doctoral degree in Cell and Molecular Biology from Rowan University. Dr. DeMarshall completed her Postdoctoral Fellowship at the New Jersey Institute for Successful Aging, at Rowan University’s School of Osteopathic Medicine. Dr. DeMarshall has published more than a dozen scientific articles in peer-reviewed journals, as well as numerous conference abstracts.

Dr. Viviano is the Director of Laboratory Operations at Durin Technologies. He received a BS in Biochemistry and Molecular Biology from Stockton University and a Ph.D. in Cell and Molecular Biology from Rowan University’s Graduate School of Biomedical Sciences. He has also completed his Postdoctoral studies at the Division of Pulmonary Medicine and Cystic Fibrosis Center at The Children’s Hospital of Philadelphia (CHOP). Dr. Viviano has produced patent-pending research, several peer reviewed, first-author publications, and dozens of abstracts at international conferences.

Dr. Krishnan is a Senior Scientist at Durin Technologies. She received her Bachelor's Degree in Biological Science from Fatima College, Madurai, India, a Masters Degree in Integrated Biology from the School of Biological Sciences, Madurai Kamaraj University, Madurai, India and her PhD. in Biochemistry from the School of Biological Sciences, Madurai Kamaraj University, Madurai, India. She brings close to 40 years of experience in the fields of Biochemistry and Neuroscience. The results of her work have resulted in 19 publications and numerous patent applications. 

Maribeth brings over two decades of experience in operations management, event planning and process improvement to her role with Durin Life Sciences.  With a strong focus on optimizing processes and enhancing organizational efficiency, Maribeth has successfully led cross-functional initiatives across industries including technology and financial services. Her expertise extends to managing complex projects and events, ensuring seamless execution while achieving strategic goals. Maribeth earned a Bachelor of Science degree in Hotel Administration from Cornell University, where she embraced the motto “Life is Service” and applies it to every facet of her professional and volunteer endeavors.

Jill joined Durin Life Sciences in January 2025.  As Director of Finance, she is responsible for overseeing and managing the financial health and strategy of the organization. Her responsibilities include financial planning, budgeting and forecasting, financial reporting, and tax compliance.  She works closely with senior leadership to align financial strategies with the company’s scientific and business objectives and plays a critical role in ensuring the company's financial sustainability while supporting its growth and innovation.

Jill is a licensed CPA with over 28 years of accounting and tax experience.  She spent 25 years with a large national CPA firm before transitioning to a financial oversight role as Director of Finance for a family of privately held companies in the biotech and financial education industries.